128 related articles for article (PubMed ID: 10587290)
21. Pharmacokinetic analysis of etoposide distribution after administration directly into the fourth ventricle in a piglet model.
Sandberg DI; Crandall KM; Koru-Sengul T; Padgett KR; Landrum J; Babino D; Petito CK; Solano J; Gonzalez-Brito M; Kuluz JW
J Neurooncol; 2010 Mar; 97(1):25-32. PubMed ID: 19688296
[TBL] [Abstract][Full Text] [Related]
22. Crossover clinical study comparing the pharmacokinetics of etoposide (75 mg) administered as 25-mg capsules three times a day versus once a day.
Aydiner A; Koyuncu H; Tas F; Topuz E; Disci R
Int J Clin Pharmacol Res; 2000; 20(1-2):21-30. PubMed ID: 11146899
[TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetics and pharmacodynamics of oral etoposide.
Toffoli G; Corona G; Sorio R; Robieux I; Basso B; Colussi AM; Boiocchi M
Br J Clin Pharmacol; 2001 Nov; 52(5):511-9. PubMed ID: 11736859
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer.
Millward MJ; Newell DR; Yuen K; Matthews JP; Balmanno K; Charlton CJ; Gumbrell L; Lind MJ; Chapman F; Proctor M
Cancer Chemother Pharmacol; 1995; 37(1-2):161-7. PubMed ID: 7497587
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
Yong WP; Desai AA; Innocenti F; Ramirez J; Shepard D; Kobayashi K; House L; Fleming GF; Vogelzang NJ; Schilsky RL; Ratain MJ
Cancer Chemother Pharmacol; 2007 Nov; 60(6):811-9. PubMed ID: 17308893
[TBL] [Abstract][Full Text] [Related]
26. Plasma etoposide catechol increases in pediatric patients undergoing multiple-day chemotherapy with etoposide.
Zheng N; Felix CA; Pang S; Boston R; Moate P; Scavuzzo J; Blair IA
Clin Cancer Res; 2004 May; 10(9):2977-85. PubMed ID: 15131033
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia.
Edick MJ; Gajjar A; Mahmoud HH; van de Poll ME; Harrison PL; Panetta JC; Rivera GK; Ribeiro RC; Sandlund JT; Boyett JM; Pui CH; Relling MV
J Clin Oncol; 2003 Apr; 21(7):1340-6. PubMed ID: 12663724
[TBL] [Abstract][Full Text] [Related]
28. Clinical and pharmacokinetic study of fractionated doses of oral etoposide in pediatric patients with advanced malignancies.
Gregianin LJ; Brunetto AL; Di Leone L; Costa TD; Santos PP; Schwartsmann G
Med Sci Monit; 2002 Sep; 8(9):PI70-7. PubMed ID: 12218955
[TBL] [Abstract][Full Text] [Related]
29. Effects of verapamil on etoposide pharmacokinetics after intravenous and oral administration in rats.
Piao YJ; Li X; Choi JS
Eur J Drug Metab Pharmacokinet; 2008; 33(3):159-64. PubMed ID: 19007041
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG).
Davidson A; Gowing R; Lowis S; Newell D; Lewis I; Dicks-Mireaux C; Pinkerton CR
Eur J Cancer; 1997 Oct; 33(11):1816-22. PubMed ID: 9470839
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.
Kaul S; Igwemezie LN; Stewart DJ; Fields SZ; Kosty M; Levithan N; Bukowski R; Gandara D; Goss G; O'Dwyer P
J Clin Oncol; 1995 Nov; 13(11):2835-41. PubMed ID: 7595746
[TBL] [Abstract][Full Text] [Related]
32. What is the optimal dose and duration of treatment with etoposide? II. Comparative pharmacokinetic study of three schedules: 1 x 100 mg, 2 x 50 mg, and 4 x 25 mg of oral etoposide daily for 21 days.
van der Gaast A; Vlastuin M; Kok TC; Splinter TA
Semin Oncol; 1992 Dec; 19(6 Suppl 14):8-12. PubMed ID: 1488657
[TBL] [Abstract][Full Text] [Related]
33. Plasma pharmacokinetics of etoposide (VP-16) after i.v. administration to children.
Eksborg S; Söderhäll S; Frostvik-Stolt M; Lindberg A; Liliemark E
Anticancer Drugs; 2000 Apr; 11(4):237-41. PubMed ID: 10898537
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors.
Sonnichsen DS; Ribeiro RC; Luo X; Mathew P; Relling MV
Clin Pharmacol Ther; 1995 Jul; 58(1):99-107. PubMed ID: 7628187
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration.
Busse D; Würthwein G; Hinske C; Hempel G; Fromm MF; Eichelbaum M; Kroemer HK; Busch FW
Naunyn Schmiedebergs Arch Pharmacol; 2002 Sep; 366(3):218-25. PubMed ID: 12172704
[TBL] [Abstract][Full Text] [Related]
36. Enhanced bioavailability of etoposide after oral or intravenous administration of etoposide with kaempferol in rats.
Li C; Li X; Choi JS
Arch Pharm Res; 2009 Jan; 32(1):133-8. PubMed ID: 19183886
[TBL] [Abstract][Full Text] [Related]
37. Oral bioavailability of etoposide after administration of a single dose to tumor-bearing dogs.
Flory AB; Rassnick KM; Balkman CE; Kiselow MA; Autio K; Beaulieu BB; Lewis LD
Am J Vet Res; 2008 Oct; 69(10):1316-22. PubMed ID: 18828689
[TBL] [Abstract][Full Text] [Related]
38. Phase I clinical and pharmacokinetic study of oral etoposide phosphate.
Sessa C; Zucchetti M; Cerny T; Pagani O; Cavalli F; De Fusco M; De Jong J; Gentili D; McDaniel C; Prins C
J Clin Oncol; 1995 Jan; 13(1):200-9. PubMed ID: 7799021
[TBL] [Abstract][Full Text] [Related]
39. Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration.
Hande K; Messenger M; Wagner J; Krozely M; Kaul S
Clin Cancer Res; 1999 Oct; 5(10):2742-7. PubMed ID: 10537337
[TBL] [Abstract][Full Text] [Related]
40. A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children.
Lowis SP; Price L; Pearson AD; Newell DR; Cole M
Br J Cancer; 1998 Jun; 77(12):2318-23. PubMed ID: 9649152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]